Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 206

1.

Ebola virus modulates transforming growth factor β signaling and cellular markers of mesenchyme-like transition in hepatocytes.

Kindrachuk J, Wahl-Jensen V, Safronetz D, Trost B, Hoenen T, Arsenault R, Feldmann F, Traynor D, Postnikova E, Kusalik A, Napper S, Blaney JE, Feldmann H, Jahrling PB.

J Virol. 2014 Sep 1;88(17):9877-92. doi: 10.1128/JVI.01410-14. Epub 2014 Jun 18.

2.

Cathepsin B & L are not required for ebola virus replication.

Marzi A, Reinheckel T, Feldmann H.

PLoS Negl Trop Dis. 2012;6(12):e1923. doi: 10.1371/journal.pntd.0001923. Epub 2012 Dec 6.

3.

Ebola virus-like particles stimulate type I interferons and proinflammatory cytokine expression through the toll-like receptor and interferon signaling pathways.

Ayithan N, Bradfute SB, Anthony SM, Stuthman KS, Dye JM, Bavari S, Bray M, Ozato K.

J Interferon Cytokine Res. 2014 Feb;34(2):79-89. doi: 10.1089/jir.2013.0035. Epub 2013 Oct 8.

4.

Niemann-pick C1 is essential for ebolavirus replication and pathogenesis in vivo.

Herbert AS, Davidson C, Kuehne AI, Bakken R, Braigen SZ, Gunn KE, Whelan SP, Brummelkamp TR, Twenhafel NA, Chandran K, Walkley SU, Dye JM.

MBio. 2015 May 26;6(3):e00565-15. doi: 10.1128/mBio.00565-15.

5.

VSVΔG/EBOV GP-induced innate protection enhances natural killer cell activity to increase survival in a lethal mouse adapted Ebola virus infection.

Williams KJ, Qiu X, Fernando L, Jones SM, Alimonti JB.

Viral Immunol. 2015 Feb;28(1):51-61. doi: 10.1089/vim.2014.0069.

PMID:
25494457
6.

Particle-to-PFU ratio of Ebola virus influences disease course and survival in cynomolgus macaques.

Alfson KJ, Avena LE, Beadles MW, Staples H, Nunneley JW, Ticer A, Dick EJ Jr, Owston MA, Reed C, Patterson JL, Carrion R Jr, Griffiths A.

J Virol. 2015 Jul;89(13):6773-81.

7.

Transcriptional correlates of disease outcome in anticoagulant-treated non-human primates infected with ebolavirus.

Garamszegi S, Yen JY, Honko AN, Geisbert JB, Rubins KH, Geisbert TW, Xia Y, Hensley LE, Connor JH.

PLoS Negl Trop Dis. 2014 Jul 31;8(7):e3061. doi: 10.1371/journal.pntd.0003061. eCollection 2014.

8.

The cytoprotective enzyme heme oxygenase-1 suppresses Ebola virus replication.

Hill-Batorski L, Halfmann P, Neumann G, Kawaoka Y.

J Virol. 2013 Dec;87(24):13795-802. doi: 10.1128/JVI.02422-13. Epub 2013 Oct 9.

9.

Ebola virus: new insights into disease aetiopathology and possible therapeutic interventions.

Geisbert TW, Hensley LE.

Expert Rev Mol Med. 2004 Sep 21;6(20):1-24. Review.

PMID:
15383160
10.

Functional CD8+ T cell responses in lethal Ebola virus infection.

Bradfute SB, Warfield KL, Bavari S.

J Immunol. 2008 Mar 15;180(6):4058-66.

11.

Different Temporal Effects of Ebola Virus VP35 and VP24 Proteins on Global Gene Expression in Human Dendritic Cells.

Ilinykh PA, Lubaki NM, Widen SG, Renn LA, Theisen TC, Rabin RL, Wood TG, Bukreyev A.

J Virol. 2015 Aug;89(15):7567-83. doi: 10.1128/JVI.00924-15. Epub 2015 May 13.

12.

Delayed Disease Progression in Cynomolgus Macaques Infected with Ebola Virus Makona Strain.

Marzi A, Feldmann F, Hanley PW, Scott DP, Günther S, Feldmann H.

Emerg Infect Dis. 2015 Oct;21(10):1777-83. doi: 10.3201/eid2110.150259.

13.

Suppressor of Cytokine Signaling 3 Is an Inducible Host Factor That Regulates Virus Egress during Ebola Virus Infection.

Okumura A, Rasmussen AL, Halfmann P, Feldmann F, Yoshimura A, Feldmann H, Kawaoka Y, Harty RN, Katze MG.

J Virol. 2015 Oct;89(20):10399-406. doi: 10.1128/JVI.01736-15. Epub 2015 Aug 5.

14.

Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis.

Kindrachuk J, Ork B, Hart BJ, Mazur S, Holbrook MR, Frieman MB, Traynor D, Johnson RF, Dyall J, Kuhn JH, Olinger GG, Hensley LE, Jahrling PB.

Antimicrob Agents Chemother. 2015 Feb;59(2):1088-99. doi: 10.1128/AAC.03659-14. Epub 2014 Dec 8.

15.
16.

Development of a murine model for aerosolized ebolavirus infection using a panel of recombinant inbred mice.

Zumbrun EE, Abdeltawab NF, Bloomfield HA, Chance TB, Nichols DK, Harrison PE, Kotb M, Nalca A.

Viruses. 2012 Dec 3;4(12):3468-93. doi: 10.3390/v4123468. Review.

17.

Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus.

Wang D, Raja NU, Trubey CM, Juompan LY, Luo M, Woraratanadharm J, Deitz SB, Yu H, Swain BM, Moore KM, Pratt WD, Hart MK, Dong JY.

J Virol. 2006 Mar;80(6):2738-46.

18.

Virus-like particles activate type I interferon pathways to facilitate post-exposure protection against Ebola virus infection.

Ayithan N, Bradfute SB, Anthony SM, Stuthman KS, Bavari S, Bray M, Ozato K.

PLoS One. 2015 Feb 26;10(2):e0118345. doi: 10.1371/journal.pone.0118345. eCollection 2015.

19.

Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model.

Oestereich L, Lüdtke A, Wurr S, Rieger T, Muñoz-Fontela C, Günther S.

Antiviral Res. 2014 May;105:17-21. doi: 10.1016/j.antiviral.2014.02.014. Epub 2014 Feb 26.

20.

Profibrogenic transforming growth factor-beta/activin receptor-like kinase 5 signaling via connective tissue growth factor expression in hepatocytes.

Weng HL, Ciuclan L, Liu Y, Hamzavi J, Godoy P, Gaitantzi H, Kanzler S, Heuchel R, Ueberham U, Gebhardt R, Breitkopf K, Dooley S.

Hepatology. 2007 Oct;46(4):1257-70.

PMID:
17657819

Supplemental Content

Support Center